Back to Search
Start Over
Does the Introduction of Biosimilars Change Our Understanding about Treatment Modalities for Inflammatory Bowel Disease?
- Source :
- Digestive diseases (Basel, Switzerland). 35(1-2)
- Publication Year :
- 2017
-
Abstract
- Background: Biological agents, mainly tumor necrosis factor-α inhibitors, play an important role in the treatment of inflammatory bowel disease (IBD). These drugs are expensive and constitute a major cost in the IBD care. In 2013, the first biosimilar monoclonal antibody, infliximab (IFX), was approved in the EU. Key Messages: There has been considerable skepticism regarding the use of biosimilars. Both clinicians and patients have questioned the safety and efficacy of these new drugs. In particular, the extrapolation of treatment effects between patients with different diagnoses has been debated. Due to national negotiations, the price reductions vary considerably between countries. In Norway, the biosimilars Remsima® and Inflectra® come at a very favourable price, and have supplanted the originator Remicade® almost completely. The total sale of IFX has also increased, indicating that extended indications and increased doses are being implemented in clinical use. Conclusions: The introduction of biosimilars has raised questions not only about the efficacy and safety but also about health politics. There is reason to believe that the introduction of cheaper biosimilars will change the clinical use of biologics.
- Subjects :
- 0301 basic medicine
medicine.medical_specialty
Inflammatory bowel disease
Gastroenterology
03 medical and health sciences
0302 clinical medicine
Gastrointestinal Agents
Internal medicine
medicine
Humans
European Union
Biosimilar Pharmaceuticals
business.industry
Norway
Antibodies, Monoclonal
Biosimilar
General Medicine
medicine.disease
Inflammatory Bowel Diseases
Ulcerative colitis
Infliximab
030104 developmental biology
Treatment modality
030211 gastroenterology & hepatology
Tumor necrosis factor alpha
business
medicine.drug
Subjects
Details
- ISSN :
- 14219875
- Volume :
- 35
- Issue :
- 1-2
- Database :
- OpenAIRE
- Journal :
- Digestive diseases (Basel, Switzerland)
- Accession number :
- edsair.doi.dedup.....9cff54d4911f30795708c301f1c0e407